Case 26-2005: A 48-year-old man with sudden loss of consciousness while jogging

New England Journal of Medicine

Volumn 353, Issue 8, 2005, Pages 824-832

  Binder, William D ^a,b   Fifer, Michael A ^a,b   King, Mary Etta ^a,b   Stone, James R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; DIFFERENTIAL DIAGNOSIS; ELECTROCARDIOGRAPHY; EMERGENCY WARD; ENDOTRACHEAL INTUBATION; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; LABORATORY TEST; MALE; NEUROLOGIC EXAMINATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYNCOPE; THORAX RADIOGRAPHY; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; ECHOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; JOGGING; MIDDLE AGED; RISK FACTOR; SUDDEN DEATH; UNCONSCIOUSNESS;

ANTIARRHYTHMIC AGENT; METOPROLOL; SOTALOL;

ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; JOGGING; MALE; METOPROLOL; MIDDLE AGED; RISK FACTORS; SOTALOL; SYNCOPE; UNCONSCIOUSNESS;

EID: 23944524860     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc059021     Document Type: Article

References (46)

1. Day SC, Cook EF, Funkenstein H, Goldman L. Evaluation and outcome of emergency room patients with transient loss of consciousness. Am J Med 1982;73:15-23.
2. Silverstein MD, Singer DE, Mulley AG, Thibault GE, Barnett GO. Patients with syncope admitted to medical intensive care units. JAMA 1982;248:1185-9.
3. Edlow JA, Caplan LR. Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage. N Engl J Med 2000;342:29-36.
4. Linzer M, Yang EH, Estes NA III, Wang P, Vorperian VR, Kapoor WN. Diagnosing syncope. 1. Value of history, physical examination, and electrocardiography. Ann Intern Med 1997;126:989-96.
5. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002;347:878-85.
6. Benditt DG, van Dijk JG, Sutton R, et al. Syncope. Curr Probl Cardiol 2004;29:152-229.
7. Kapoor WN. Syncope. N Engl J Med 2000;343:1856-62.
8. American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of patients presenting with syncope. Ann Emerg Med 2001;37:771-6.
9. Safar P, Behringer W, Bottiger BW, Sterz F. Cerebral resuscitation potentials for cardiac arrest. Crit Care Med 2002;30:Suppl:S140-S144.
10. Booth CM, Boone RH, Tomlinson G, Detsky AS. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. JAMA 2004;291:870-9.
11. Bergfeldt L. Differential diagnosis of cardiogenic syncope and seizure disorders. Heart 2003;89:353-8.
12. Martin GJ, Adams SL, Martin HG, Mathews J, Zull D, Scanlon PJ. Prospective evaluation of syncope. Ann Emerg Med 1984;13:499-504.
13. Alboni P, Brignole M, Menozzi C, et al. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol 2001;37:1921-8.
14. The works of John Hunter . . . with notes. Palmer JF, ed. London: Longman, Rees, Orme, Brown, Green, and Longman, 1837.
15. Fenton AM, Hammill SC, Rea RF, Low PA, Shen WK. Vasovagal syncope. Ann Intern Med 2000;133:714-25.
16. Heaven DJ, Sutton R. Syncope. Crit Care Med 2000;28:Suppl:N116-N120.
17. Sarasin FP, Louis-Simonet N, Carballo D, et al. Prospective evaluation of patients with syncope: a population-based study. Am J Med 2001;111:177-84.
18. Frenneaux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 2004;90:570-5.
19. Ommen SR, Nishimura RA. Hypertrophic cardiomyopathy. Curr Probl Cardiol 2004;29:239-91.
20. Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology 2004;44:412-27.
21. Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy - pathology and pathogenesis. Histopathology 1995;26:493-500.
22. Fatkin D, Graham RM. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 2002;82:945-80.
23. Lombardi R, Betocchi S. Aetiology and pathogenesis of hypertrophic cardiomyopathy. Acta Paediatr Suppl 2002;91:10-4.
24. Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:1776-82.
25. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84:476-82.
26. Tsybouleva N, Zhang L, Chen S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004;109:1284-91.
27. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-24.
28. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:789-91.
29. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
30. Nishimura RA, Holmes DR Jr. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004;350:1320-7. [Erratum, N Engl J Med 2004;351:1038.]
31. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Document and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-713. (Also available at http://www.acc.org/clinical/consensus/ cardiomyopathy/index.pdf.)
32. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
33. Spirito P, Bellone P, Harris KM, Bernabò P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
34. Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:206-11.
35. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathyrelated death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
36. Maron BJ, Roberts WC, McAllister HA, Rosing DR, Epstein SE. Sudden death in young athletes. Circulation 1980;62:218-29.
37. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:1064-75.
38. Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes: insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995;91:1596-601.
39. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;42:873-9.
40. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-8.
41. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24:880-5.
42. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004;109:2807-16.
43. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975;52:88-102.
44. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-4.
45. Jayatilleke I, Doolan A, Ingles J, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004;93:1192-4.
46. Maron BJ, Carney KP, Lever HM, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:974-80.